UK markets open in 2 hours 2 minutes

OSE Immunotherapeutics SA (0RAD.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
5.00+0.25 (+5.34%)
At close: 05:12PM GMT

OSE Immunotherapeutics SA

22, boulevard Benoni Goulin
Nantes 44200
France
33 2 28 29 10 10
https://www.ose-immuno.com

Sector(s)
Industry
Full-time employees62

Key executives

NameTitlePayExercisedYear born
Dr. Dominique Costantini M.D.Founder, Chairman of the Board and Director of Development & Strategy404.11kN/A1956
Dr. Nicolas Poirier Ph.D.General Director, CEO, Scientific Director & Director350.15kN/A1982
Ms. Anne-Laure Autret-CornetCFO, Administrative & Financial Director and Employee Shareholder Representative DirectorN/AN/AN/A
Mr. Alexis PeyrolesConsultant586.59kN/A1974
Dr. Alain Chatelin M.D.Medical DirectorN/AN/AN/A
Bérangère Vasseur M.D.Chief Medical Officer Immuno-OncologyN/AN/AN/A
Mr. Julien PerrierChief Commercial OfficerN/AN/AN/A
Ms. Linda Lebon M.Sc.Chief Regulatory OfficerN/AN/A1967
Dr. Silvia Comis M.D.Head of Clinical DevelopmentN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.

Corporate governance

OSE Immunotherapeutics SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.